Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of a transaction involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding an executive share award rather than a financial performance report.
Material Changes
The material change reported is an increase in the shareholding of Mr. Jean Stéphenne, President and General Manager of GlaxoSmithKline Biologicals. On July 22, 2009, he received an award of 2,500 Ordinary Shares under the GlaxoSmithKline R&D Employee Inventor Award Programme. This award recognizes his role as an inventor of Flu Pre-Pandemic (D-PAN) Vb61316 upon the product's first launch in a major market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction involves shares with no restrictions attached, and the price of an Ordinary Share on the award date was £11.53.
Key Facts for Investor Verification
- Recipient: Mr. Jean Stéphenne, President and General Manager, GlaxoSmithKline Biologicals.
- Award Details: 2,500 Ordinary Shares granted on July 22, 2009.
- Programme: GlaxoSmithKline R&D Employee Inventor Award Programme (established December 2007).
- Underlying Asset: Recognition for invention related to Flu Pre-Pandemic (D-PAN) Vb61316.
- Share Price: £11.53 on the date of award.
- Restrictions: None attached to the awarded shares.